Pregnancy and childbirth in patients with Glanzmann Thrombasthenia.
bleeding disorders
platelet disorders
pregnancy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
03
03
2024
accepted:
03
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
aheadofprint
Résumé
Glanzmann thrombasthenia (GT) is a rare inherited platelet bleeding disorder caused by a quantitative and/or qualitative defect of the αIIbβ3 integrin. Pregnancy and delivery pose special challenges as they entail increased risks of both maternal and foetal bleeding that may be life-threatening. Multidisciplinary management throughout the preconception, intrapartum and peripartum periods is vital to optimize pregnancy outcomes. This Nutshell review focuses on the challenging management of pregnancy and childbirth in patients with GT.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost. 2013;39(6):642–655.
Grainger JD, Thachil J, Will AM. How we treat the platelet glycoprotein defects: Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol. 2018;182(5):621–632.
World‐Federation‐of‐Hemophilia. Report on the Annual Global Survey 2022. [cited 2024 February 22]. Available from: https://www1.wfh.org/publications/files/pdf‐2399.pdf.
Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia. 2011;17(5):e858–e869.
Fiore M, Sentilhes L, d'Oiron R. How I manage pregnancy in women with Glanzmann thrombasthenia. Blood. 2022;139:2632–2641.
Buitrago L, Rendon A, Liang Y, Simeoni I, Negri A, ThromboGenomics Consortium, et al. αIIbβ3 variants defined by next‐generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. Proc Natl Acad Sci U S A. 2015;112(15):E1898–E1907.
Coller BS, Seligsohn U, Zivelin A, Zwang E, Lusky A, Modan M. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann's thrombasthenia in Iraqi‐Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol. 1986;62(4):723–735.
Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi‐Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A. 1991;88(8):3160–3164.
Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T, Corke S, et al. International collaboration for transfusion medicine guidelines (ICTMG). Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence‐based practice, an international approach. Br J Haematol. 2019;185(3):549–562.
Regan F, Lees CC, Jones B, Nicolaides KH, Wimalasundera RC, Mijovic A, et al. Prenatal management of pregnancies at risk of fetal neonatal alloimmune thrombocytopenia (FNAIT): scientific impact paper no. 61. BJOG. 2019;126(10):e173–e185.
Santoso S, Wihadmadyatami H, Bakchoul T, Werth S, al‐Fakhri N, Bein G, et al. Antiendothelial avb3 antibodies are a major cause of intracranial bleeding in fetal/ neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol. 2016;36(8):1517–1524.
Ghi T, Sotiriadis A, Calda P, Da Silva CF, Raine‐Fenning N, Alfirevic Z, et al. International society of ultrasound in obstetrics and gynecology (ISUOG). ISUOG practice guidelines: invasive procedures for prenatal diagnosis. Ultrasound Obstet Gynecol. 2016;48:256–268.
Huisman EJ, Holle N, Schipperus M, Cnossen MH, de Haas M, Porcelijn L, et al. Should HLA and HPA‐matched platelet transfusions for patients with Glanzmann Thrombasthenia or Bernard‐Soulier syndrome be standardized care? A Dutch survey and recommendations. Transfusion. 2024;64(5):824–838.
Fiore M, Giraudet JS, Alessi MC, Falaise C, Desprez D, d'Oiron R, et al. Emergency management of patients with Glanzmann thrombasthenia: consensus recommendations from the French reference center for inherited platelet disorders. Orphanet J Rare Dis. 2023;18(1):171.
Hauschner H, Rosenberg N, Seligsohn U, Mendelsohn R, Simmonds A, Shiff Y, et al. Persistent neonatal thrombocytopenia can be caused by IgA antiplatelet antibodies in breast milk of immune thrombocytopenic mothers. Blood. 2015;126:661–664.
Schaedel ZE, Dolan G, Powell MC. The use of levonorgestrel releasing intrauterine system in the management of women with hemostatic disorders. Am J Obstet Gynecol. 2005;193:1361–1363.
Vricella LK, Gawron LM, Louis JM. Society for Maternal‐Fetal Medicine (SMFM) consult series #48: immediate postpartum long‐acting reversible contraception for women at high risk for medical complications. Am J Obstet Gynecol. 2019;220(5):B2–B12.
Carvalho T. Janssen's nipocalimab tackles hemolytic disease of the fetus and newborn. Nat Med. 2023;29(4):757–758.
Gandhi PS, Zivkovic M, Østergaard H, Bonde AC, Elm T, Løvgreen MN, et al. A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders. Nat Cardiovasc Res. 2024;3:166–185.